Problems › Where Should We Invest Next? › Professional Services
Capital allocation goes wrong when the loudest line gets funded rather than the one with the best return on the next dollar. This page works through it for professional services firms specifically — including an unedited excerpt from a real analysis of a professional services firm.
Capital allocation goes wrong when the loudest line gets funded rather than the one with the best return on the next dollar. Professional services firms carry a specific bind here — partner compensation rationally pays people not to sell the highest-margin product in the firm. Until that is priced, billable utilisation will keep moving for reasons nobody can attribute, and the debate about return by line will stay a matter of opinion.
Most businesses allocate by history and by advocacy: the lines that got money last year get it again, and the person who argues best gets the increment. Neither has anything to do with where the next dollar earns most.
The analysis that helps ranks each line on two things — what it returns on incremental investment, and how durable that return is. A line that returns well but decays in eighteen months is a different proposition from one that returns modestly for a decade, and treating them as comparable is how businesses end up funding decline.
The output should be a sequence with a stopping rule, not a budget split. Which one first, what it funds next, and the observation that would say the sequence is wrong.
These three together are the signature. One on its own usually points somewhere else.
✓ Budgets are set by last year plus a percentage
✓ Nobody can rank the lines by return on incremental investment
✓ Investment decisions are defended by strategic importance rather than by arithmetic
The move that usually makes it worse. Spreading capital evenly to keep the peace, which underfunds the one thing that would have compounded.
It is for you if you run or finance a professional services firm and budgets are set by last year plus a percentage. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a professional services firm. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Aldergate Partners, a sample company profile used for testing rather than a customer — $88M revenue, 310 people.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Re-align partner economics so the $85K diagnostic becomes the highest-compensated path to the $410K implementation.
The leak it closes. Partner-level incentive leakage that currently diverts 25% of diagnostic-eligible opportunities back to T&M work
The assumption it rests on. 15-of-22 partners approve compensation redesign within 60 days — the engine put the probability at 0.7.
| Investment required | $700K total over 36 months — $200K annual incentive pool × 3 years + $100K legal and change-management cost |
| Expected return | 3.4× cash-on-cash over 36 months (NPV $2.4M / $700K investment) on $58.0M current revenue base |
| Revenue, year 1 | +$1.2M incremental diagnostic and implementation revenue (15 additional diagnostics × $85K + 12 conversions × $410K) |
| Revenue, year 2 | +$2.4M cumulative incremental revenue |
| Revenue, year 3 | +$3.7M cumulative incremental revenue |
| Exit criteria | Terminate this move and revert to legacy compensation if (a) fewer than 12-of-22 partners approve redesign by Day 60, or (b) any top-3 account issues an RFP within 90 days of announcement, or (c) diagnostic-to-implementation conversion falls below 10-of-19 by December 31, 2026. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For professional services firms it works through billable utilisation, realisation, revenue per partner and engagement gross margin, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
Price the durability explicitly. A return that decays needs a stated half-life; once each option carries one, options with different horizons become comparable rather than a matter of taste.
Usually the strongest, because that is where a marginal dollar compounds. Fixing the weakest is worth doing when it is a constraint on the strongest, and not otherwise.
Then decide on reversibility. When two options return similarly, take the one you can stop, because the value of the information you buy exceeds the difference in the estimates.
Materially, yes. Partner compensation rationally pays people not to sell the highest-margin product in the firm — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are billable utilisation, realisation, revenue per partner, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on billable utilisation and realisation. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.